In a move that could impact rival companies, Pfizer has halted its efforts to develop an oral weight management treatment due to a serious safety issue. The decision comes after one patient fell ill while participating in the clinical trial, prompting the pharmaceutical giant to suspend further development of the experimental drug. This news is significant for companies like Eli Lilly and Novo Nordisk, which are also working on obesity treatments.
Source: https://www.barrons.com/articles/pfizer-eli-lilly-novo-stock-price-obesity-drug-304c7c2f